Carmat has opened a second production facility in Bois-d’Arcy.
Works on the site, which is in the immediate vicinity of the company’s first production facility, have been completed, and the entire facility has been reviewed by the notified body DEKRA, which in mid-November 2023 approved it for the production of the Aeson total artificial heart.
The Aeson total artificial heart is aimed at providing a therapeutic alternative for patients suffering from advanced biventricular heart failure
The new 1,500m2 building will enable Carmat to significantly increase its capacity in terms of the assembly of the electronic parts of the Aeson heart, microbiological testing of the product and the manufacturing process, receiving and checking incoming components, and storage and shipping, the company says.
Combined with the extension of the clean room which is currently being completed in the “BDA1” facility, the opening of the “BDA2” facility will enable the company to reach an annual production capacity of 500 hearts by early 2024, it states.
Stéphane Piat, chief executive officer of CARMAT, comments: “The opening of our new production facility is a major achievement, and I would like to thank all the teams who have worked relentlessly to ensure that it is delivered on schedule before the end of 2023. Today, with the historical “BDA1” facility and this new “BDA2” facility, we have a high-performance manufacturing tool that is certified to produce up to 500 hearts per year from 2024. In line with our strategic plan, we will further develop our industrial set-up over the next few years, to reach an annual production capacity of 1,000 Aeson hearts by 2027.”
